Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.

Bibliographic Details
Main Authors:	Locklin, R, Croucher, P, Russell, R, Shipman, C
Format:	Conference item
Published:	2005

Similar Items

Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment.
by: Locklin, R, et al.
Published: (2007)

Differential sensitivity of normal osteoblast-like cells and osteosarcoma cells to TRAIL and an agonist antibody to TRAIL receptor-2
by: Locklin, R, et al.
Published: (2005)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
by: Shipman, C, et al.
Published: (2002)

Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis.
by: Locklin, R, et al.
Published: (2007)

Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.
by: Nyambo, R, et al.
Published: (2004)

Human bone marrow stromal cells protect prostate and breast cancer cells from TRAIL-induced apoptosis
by: Nyambo, R, et al.
Published: (2004)

The Bone Marrow Microenvironment in Multiple Myeloma
by: Edwards, C
Published: (2010)

Osteoblasts protect multiple myeloma cells from T-cell-induced apoptosis
by: Locklin, R, et al.
Published: (2007)

Selective targeting of DR5 circumvents resistance of MG-63 osteosarcoma to trail-induced apoptosis
by: Locklin, R, et al.
Published: (2006)

TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis
by: Singh, HD, et al.
Published: (2017)

Nitrogen-containing bisphosphonates induce apoptosis in human bone marrow-derived myeloma cells in vitro by inhibiting protein prenylation.
by: Gordon, S, et al.
Published: (1999)

Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL.
by: Mongkolsapaya, J, et al.
Published: (1998)

Expression of TRAIL and TRAIL receptors in normal and malignant tissues.
by: Daniels, R, et al.
Published: (2005)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
by: De Leenheer, E, et al.
Published: (2004)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
by: Shipman, C, et al.
Published: (2002)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
by: De Leenheer, E, et al.
Published: (2002)

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.
by: Shipman, C, et al.
Published: (1997)

The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
by: Shipman, C, et al.
Published: (1998)

The importance of the bone marrow microenvironment in multiple myeloma; Differential responses to lithium in vivo
by: Edwards, C, et al.
Published: (2006)

Targeting cell spreading: a method of sensitizing metastatic tumor cells to TRAIL-induced apoptosis.
by: Phipps, L, et al.
Published: (2011)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
by: Shipman, C, et al.
Published: (2000)

Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.
by: Edwards, C, et al.
Published: (2009)

Targeting cell adhesion as a method of sensitising metastatic tumour cells to TRAIL-induced apoptosis
by: Phipps, L
Published: (2011)

Osteoprotegerin and the development of myeloma bone disease
by: Croucher, P, et al.
Published: (2004)

The ubiquitin-proteasome pathway is dysregulated in myeloma cells in the bone microenvironment in vivo
by: Edwards, C, et al.
Published: (2007)

Urban trails : a preliminary list of trails and sources/
by: 409605 Goodey, Brian
Published: (1974)

Kafka's trail
by: McLees, F
Published: (2020)

The Oregan trail /
by: 350759 Parkman, Francis
Published: (1931)

The paradise trail /
by: Campbell, Duncan, author
Published: (2008)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
by: Shipman, C, et al.
Published: (2003)

Engineered nanomedicine for myeloma and bone microenvironment targeting
by: Swami, Archana, et al.
Published: (2015)

Bone marrow adiposity and multiple myeloma
by: Morris, E, et al.
Published: (2018)

NE10790, a phosphonocarboxylate analogue of risedronate, induces human myeloma cell apoptosis in vitro
by: Roelofs, A, et al.
Published: (2004)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
by: Croucher, P, et al.
Published: (2002)

Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo.
by: Edwards, C, et al.
Published: (2008)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
by: Shipman, C, et al.
Published: (2000)

Anti-tumour activity of bisphosphonates in human myeloma cells.
by: Shipman, C, et al.
Published: (1998)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
by: Croucher, P, et al.
Published: (2003)

Physical impact indicators for mountain trails at Gunung Tahan Trail, Malaysia
by: Yaakob, Sam Shor Nahar
Published: (2019)

Trailing Pahang’s heritage
by: Aisyah Hanum, Abu Bakar
Published: (2010)